Overview

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Status:
Active, not recruiting

Trial end date:
2022-06-27

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Carboplatin
Cetuximab
Cisplatin
Fluorouracil
Pembrolizumab